1. EPWORTH Knowedge Bank
  2. Academic & Clinical
  3. UroRenal, Vascular
Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/2010
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHarewood, Laurence-
dc.contributor.authorLawrentschuk, Nathan-
dc.contributor.authorTroy, Andrew-
dc.contributor.authorWebb, David-
dc.contributor.authorChan, Yee-
dc.contributor.authorMurphy, Declan-
dc.contributor.authorTran, Ben-
dc.contributor.otherAnton, Angelyn-
dc.contributor.otherHasan, Olfat-
dc.contributor.otherBallok, Zita-
dc.contributor.otherBowden, Patrick-
dc.contributor.otherCostello, Anthony-
dc.contributor.otherDundee, Philip-
dc.contributor.otherPeters, Justin-
dc.contributor.otherSee, Andrew-
dc.contributor.otherShankar, Siva-
dc.contributor.otherHofman, Michael-
dc.date.accessioned2021-07-22T05:36:15Z-
dc.date.available2021-07-22T05:36:15Z-
dc.date.issued2020-10-
dc.identifier.citationBJU Int . 2020 Oct;126(4):433-435en_US
dc.identifier.issn1464-410Xen_US
dc.identifier.urihttp://hdl.handle.net/11434/2010-
dc.description.abstractOur study investigated the use of Prostate-specific membrane antigen (PSMA) positron-emission tomography (PET/CT) in patients with metastatic prostate cancer who received upfront chemohormonal therapy. The aim was to compare metabolic response assessed by PSMA PET/CT with the established favourable prognostic marker of PSA ≤0.2 ng/mL following chemotherapy.en_US
dc.publisherWileyen_US
dc.subjectProstate-Specofic Membrane Antigenen_US
dc.subjectPSMAen_US
dc.subjectPositron-Emission Tomographyen_US
dc.subjectPET/CTen_US
dc.subjectMetastatic Prostate Canceren_US
dc.subjectUpfront Chemohormonal Therapyen_US
dc.subjectMetabolic Responseen_US
dc.subjectPrognostic Markeren_US
dc.subjectChemotherapyen_US
dc.subjectEpworth Cancer Services Clinical Instituteen_US
dc.subjectEpworth Urology and Vascular Clinical Instituteen_US
dc.titleUse of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer.en_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1111/bju.15151en_US
dc.identifier.journaltitleBJU Internationalen_US
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/32579772/en_US
dc.description.affiliatesWalter and Eliza Hall Institute, Melbourne, Vic., Australia.en_US
dc.description.affiliatesPeter MacCallum Cancer Centre, Melbourne, Vic., Australia.en_US
dc.description.affiliatesHamilton Health Sciences, McMaster University, Hamilton, ON, Canada.en_US
dc.description.affiliatesHealthcare Imaging Services, Melbourne, Vic., Australia.en_US
dc.description.affiliatesICON Cancer Care, Melbourne, Vic., Australia.en_US
dc.description.affiliatesRoyal Melbourne Hospital, Melbourne, Vic., Australia.en_US
dc.description.affiliatesAustralian Prostate Centre, Melbourne, Vic., Australia.en_US
dc.description.affiliatesDepartment of Surgery, University of Melbourne, Melbourne, Vic., Australia.en_US
dc.description.affiliatesSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.en_US
dc.type.studyortrialCohort Studyen_US
dc.type.contenttypeTexten_US
Appears in Collections:UroRenal, Vascular

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.